Non-Hodgkin Lymphoma Clinical Trial
— ALDIOfficial title:
Administration of LMP1- and LMP2- Specific Cytotoxic T-Lymphocytes Following CD45 Antibody to Patients With Relapsed EBV-Positive Hodgkin's or Non-Hodgkin's Lymphoma or Chronic Active EBV Infection (ALDI)
Verified date | May 2012 |
Source | Baylor College of Medicine |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
The purpose of this study is to obtain blood (up to 90 ml or 18-teaspoonfuls on one or two
occasions) to make LMP1- and LMP2-cytotoxic T-lymphocytes and grow them in the laboratory in
such a way that they are able to attack LMP1- and LMP2-positive cells in the laboratory.
If we are successful in growing these cells and if we feel they would be helpful to the
donor, we would then give the cells back to the donor.
This trial is for patients that have a type of lymph gland cancer called Hodgkin or
non-Hodgkin lymphoma, or chronic active Epstein Barr virus (EBV) infection, which has come
back or not gone away after treatment, including the best treatment we know.
This is a research study using special immune system cells called LMP1- and LMP2-specific
cytotoxic T lymphocytes (LMP1- and LMP2-CTLs), a new experimental therapy. As in chronic
active EBV infection, some patients with Hodgkin or non-Hodgkin lymphoma show evidence of
infection with the virus that causes infectious mononucleosis (EBV) before or at the time of
their diagnosis of the Lymphoma. EBV is found in the cancer cells of up to half the patients
with lymphoma, suggesting that it may play a role in causing lymphoma. The cancer cells
infected by EBV are able to hide from the body's immune system and escape destruction. We
want to see if special white blood cells, called T cells, that have been trained to kill EBV
infected cells can survive in the patient's blood and affect EBV-positive cells. In this
present study we are trying to find out if we can improve this treatment by growing T cells
that only recognize two of the proteins expressed on lymphoma cells called LMP1 and LMP2.
These special T cells are called LMP1- and LMP2-specific cytotoxic CTLs.
Status | Terminated |
Enrollment | 6 |
Est. completion date | February 2010 |
Est. primary completion date | February 2010 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: Diagnosis of EBV-positive Hodgkin's disease (HD), non-Hodgkin's lymphoma (NHL; all histological subtypes except Burkitt's lymphoma), or EBV (associated)-T/NK-LPD, or chronic active EBV infection (CAEBV) after second or subsequent relapse including after autologous or syngeneic stem cell transplant (or first relapse or with active disease if immunosuppressive chemotherapy contraindicated). CAEBV is defined as i) illness for greater than 3 months duration (EBV-related illness or symptoms including fever, persistent hepatitis, extensive lymphadenopathy, or hepatosplenomegaly); ii) increased amounts of EBV-DNA in peripheral blood (equal or greater than 400 genome copies per ug of DNA) or abnormal high levels of EBV antibodies (VCA IgG equal or greater than 1:5120 or EA IgG equal or greater than 1:640; and iii) no evidence of previous immunological abnormalities or other recent infection that might explain the observed condition. Patients with life expectancy greater than 6 weeks. Patients with a Karnofsky score (age =16) of greater than 50 or Lansky score (age<16) of greater than 50 No severe intercurrent infection. HIV negative donor (if autologous donor, patient must be HIV negative) Patient, parent/guardian able to give informed consent. Patients with bilirubin less than3 x normal, AST less than 5 x normal, and Hgb greater than 8.0 Patients with a creatinine less than 2 x normal for age Patients should have been off other investigational therapy including T cell therapies for one month prior to entry in this study. Female patients with reproductive capacity must have a negative pregnancy test. Women of childbearing potential must not be pregnant and must be on effective birth control. The male partner should use a condom. Note: Patients who would be excluded from the protocol strictly for laboratory abnormalities can be included at the investigator¡¦s discretion after approval by the CAGT Protocol Review Committee and the FDA reviewer. Exclusion Criteria: - Patient, parent/guardian unable or unwilling to give informed consent - Pregnant women - Patients with a Karnofsky score of < 50 - Patients with a severe intercurrent infection - Patients with a life expectancy of <6 weeks - Patients with a bilirubin greater than 3x normal. AST greater than 5x normal and Hgb less than 8.0 g/dl - Patients with a creatinine greater than 2x normal for age - Due to unknown effects of this therapy on a fetus, pregnant women are excluded from this research. The male partner should use a condom. Note: Patients who would be excluded from the protocol strictly for laboratory abnormalities can be included at the investigator's discretion after approval by the CCGT Protocol Review Committee and the FDA reviewer. |
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Texas Children's Hospital | Houston | Texas |
United States | The Methodist Hospital | Houston | Texas |
Lead Sponsor | Collaborator |
---|---|
Baylor College of Medicine | Texas Children's Hospital, The Methodist Hospital System |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Dose limiting Toxicity: Two patients in each cohort are followed | 6 weeks post CTL infusion | Yes | |
Primary | Safety: All patients who received CD45 MAbs and LMP1- and LMP2-CTL infusions will be included in the safety analysis of this combination regimen | 1 year | Yes | |
Secondary | Laboratory data which includes CBC, BUN, creatinine, etc. will be examined at pre-infusion, and at 1, 2, 4, 6, 8 weeks post- CTL infusion, 3-month intervals for the first year | 1 year | Yes | |
Secondary | Frequency of T cells specific for LMP1-, LMP2-, and other EBV-antigens as well as T cell specific for CMVpp65 will be measured and summarized at pre and post-infusion time points | 1 year | No | |
Secondary | Changes of T cells specific for LMP1-, LMP2-, and other EBV-antigens as well as for CMVpp65 from pre-infusion to each time point of post-infusion in the overall patient group. | 1 year | No | |
Secondary | Analysis of immunologic function of tetramer-positive cells in peripheral blood, and EBV-DNA in plasma will be performed at each time point of follow-up and paired comparisons of changes from baseline will be performed. | 1 year | No | |
Secondary | Frequency of T cells specific for adenovirus and EBV. | 1 year | No | |
Secondary | Analysis of anti-tumor activity; Overall response rates as well as by dose groups will be presented after the end of CTL infusion. | 8 weeks | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01947140 -
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03755414 -
Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
|
Phase 1 | |
Recruiting |
NCT05019976 -
Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma
|
N/A | |
Active, not recruiting |
NCT04082936 -
A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma
|
Phase 1/Phase 2 | |
Completed |
NCT01527045 -
Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies
|
Phase 2 | |
Completed |
NCT04666025 -
SARS-CoV-2 Donor-Recipient Immunity Transfer
|
||
Recruiting |
NCT06018129 -
A First-in-human Trial of GEN3017 in Hodgkin Lymphoma and Non-Hodgkin Lymphoma
|
Phase 1/Phase 2 | |
Completed |
NCT02543879 -
Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies
|
Phase 1 | |
Completed |
NCT01939327 -
Safety and Efficacy of Revlimid® (Lenalidomide) With Mabthera® (Rituximab) in Non-Hodgkin's Lymphoma
|
Phase 2 | |
Completed |
NCT00503451 -
A Study to Investigate the Effects of Ketoconazole on LBH589 in Patients With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT01010295 -
A Clinico-Pathological Study to Investigate the Possible Infective Causes of Non-Hodgkin Lymphoma of the Ocular Adnexae
|
Phase 2 | |
Completed |
NCT00509379 -
Non-randomized Safety Study With Bortezomib/Rituximab in Relapsed/Refractory Indolent Lymphoma
|
Phase 2 | |
Completed |
NCT00992446 -
Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma
|
Phase 2 | |
Recruiting |
NCT05066958 -
Ex-vivo Primed Memory Donor Lymphocyte Infusion to Boost Anti-viral Immunity After T-cell Depleted HSCT
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05205512 -
Telehealth Exercise Intervention to Improve Cardiovascular Health in Lymphoma Survivors, TECHS Trial
|
N/A | |
Recruiting |
NCT05006716 -
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
|
Phase 1/Phase 2 | |
Completed |
NCT03297424 -
A Study of PLX2853 in Advanced Malignancies.
|
Phase 1 | |
Completed |
NCT02767388 -
Electrophysiological Biomarkers of Chemotherapy-related Cognitive Impairment and Recovery
|
||
Active, not recruiting |
NCT03997968 -
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT04136756 -
NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma
|
Phase 1 |